Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging

被引:12
作者
Brochot, Celine [1 ]
Bessoud, Bertrand
Balvay, Daniel
Cuenod, Charles-Andre
Siauve, Nathalie
Bois, Frederic Y.
机构
[1] INERIS, Unite Toxicol Expt, F-60550 Verneuil En Halatte, France
[2] Fac Necker, Lab Rech Imagerie, LRI U494, F-75015 Paris, France
[3] Hop Europeen Georges Pompidou, Serv Radiol, F-75015 Paris, France
关键词
tumor microcirculation; Bayesian analysis; PBPK model; Vistarem; dynamic MRI;
D O I
10.1016/j.mri.2006.04.002
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
A physiological pharmacokinetic (PBPK) model was used to estimate tumor microcirculation in nude mice with a grafted tumor. The kinetics of a rapid clearance blood pool agent, Vistarem, were investigated by dynamic MRI after bolus administration. Signal enhancements were recorded in arterial blood and in tumor tissue. To analyze these data, we developed a whole-body mathematical model of the agent's biodistribution using physiological parameters. The model included six compartments: arterial and venous plasma, tumor (split into capillaries and interstitium), and the rest of the body (also split into capillaries and interstitium). As an application, changes in tumor microcirculation parameters were evaluated in mice receiving either an antiangiogenic treatment (ZD4190) or a placebo. The analysis was performed in a Bayesian framework, and the model was fitted to experimental data using Markov Chain Monte Carlo techniques. Results showed a significant difference in tumor microcirculation between the two groups of mice when the microcirculation parameters are considered together. This whole-body physiological model enables to analyze jointly data in tumor tissue and in arterial blood. This leads to accurate estimates of microcirculation parameters and the evaluation of their uncertainty. (C) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1059 / 1067
页数:9
相关论文
共 31 条
[1]  
Bernardo J., 2009, Bayesian theory
[2]   Statistical issues in toxicokinetic modeling: A Bayesian perspective [J].
Bernillon, P ;
Bois, FY .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2000, 108 :883-893
[3]  
Bischoff KB, 1966, CHEM ENG PROG S, V62, P33
[4]  
Bois F.Y., 1997, J STAT SOFTWARE, V2
[5]   BIOEQUIVALENCE - PERFORMANCE OF SEVERAL MEASURES OF EXTENT OF ABSORPTION [J].
BOIS, FY ;
TOZER, TN ;
HAUCK, WW ;
CHEN, ML ;
PATNAIK, R ;
WILLIAMS, RL .
PHARMACEUTICAL RESEARCH, 1994, 11 (05) :715-722
[6]   PHARMACOKINETIC PARAMETERS IN CNS GD-DTPA ENHANCED MR IMAGING [J].
BRIX, G ;
SEMMLER, W ;
PORT, R ;
SCHAD, LR ;
LAYER, G ;
LORENZ, WJ .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1991, 15 (04) :621-628
[7]   Physiological parameter values for physiologically based pharmacokinetic models [J].
Brown, RP ;
Delp, MD ;
Lindstedt, SL ;
Rhomberg, LR ;
Beliles, RP .
TOXICOLOGY AND INDUSTRIAL HEALTH, 1997, 13 (04) :407-484
[8]   Quantification of the extraction fraction for gadopentetate across breast cancer capillaries [J].
Daldrup, HE ;
Shames, DM ;
Husseini, W ;
Wendland, MF ;
Okuhata, Y ;
Brasch, RC .
MAGNETIC RESONANCE IN MEDICINE, 1998, 40 (04) :537-543
[9]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[10]   Physiological pharmacokinetic analysis using population modeling and informative prior distributions [J].
Gelman, A ;
Bois, F ;
Jiang, JM .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1996, 91 (436) :1400-1412